Raj G, Kumar R, McKinney W P
Section of General Internal Medicine, Dallas Veterans Affairs Medical Center, and Department of Medicine, University of Texas Southwestern Medical Center, 75216, USA.
Arch Intern Med. 1999;159(22):2721-4. doi: 10.1001/archinte.159.22.2721.
Excessive anticoagulation increases the risk of hemorrhagic complications associated with oral anticoagulant therapy. Oral or parenteral phytonadione is used to reverse excessive anticoagulation. Intravenous (IV) phytonadione, while effective, is associated with a small risk of serious anaphylactic reactions. Subcutaneous (SC) administration is safer, but there is little information on its relative efficacy in small doses.
Twenty-two patients with asymptomatic prolongation of prothrombin time were prospectively randomized and treated with 1 mg of phytonadione IV or 1 mg SC. Prothrombin time was measured at baseline and at 8 and 24 hours after phytonadione administration and expressed as international normalized ratio (INR).
Mean INR at baseline was 8.0 and 8.5 in the IV and SC groups, respectively (P = .70). At 8 hours, mean INR was 4.6 in the IV group and 8.0 in the SC group (P = .006), and at 24 hours, mean INR was 3.1 in the IV group and 5.0 in the SC group (P = .009). Mean decrease in INR 8 hours after administration of phytonadione was 3.4 in the IV group and 0.4 in the SC group (P = .02), and mean decrease in INR after 24 hours was 4.9 in the IV group and 3.4 in the SC group (P = .18).
For patients who are excessively anticoagulated with warfarin, small doses of SC phytonadione may not correct the INR as rapidly or as effectively as when administered IV. Higher doses must be considered for more rapid and complete reversal of anticoagulation by the SC route.
抗凝过度会增加口服抗凝治疗相关出血并发症的风险。口服或胃肠外给予维生素K1可用于逆转抗凝过度。静脉注射维生素K1虽有效,但有发生严重过敏反应的小风险。皮下注射更安全,但关于小剂量皮下注射相对疗效的信息较少。
22例凝血酶原时间无症状延长的患者被前瞻性随机分组,分别接受1mg静脉注射或皮下注射维生素K1治疗。在基线时以及维生素K1给药后8小时和24小时测量凝血酶原时间,并表示为国际标准化比值(INR)。
静脉注射组和皮下注射组基线时的平均INR分别为8.0和8.5(P = 0.70)。8小时时,静脉注射组的平均INR为4.6,皮下注射组为8.0(P = 0.006);24小时时,静脉注射组的平均INR为3.1,皮下注射组为5.0(P = 0.009)。维生素K1给药后8小时,静脉注射组INR的平均下降值为3.4,皮下注射组为0.4(P = 0.02);24小时后,静脉注射组INR的平均下降值为4.9,皮下注射组为3.4(P = 0.18)。
对于华法林抗凝过度的患者,小剂量皮下注射维生素K1纠正INR的速度和效果可能不如静脉注射。若要通过皮下途径更快、更完全地逆转抗凝作用,必须考虑使用更高剂量。